Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.

The agency announced on November 2, 2011 that it had approved Edwards Lifesciences' first-generation Sapien TAVR device for patients with severe aortic stenosis who are ineligible for open-heart ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published an expert consensus statement that provides ...

The Transcatheter Aortic Valve Replacement Market primarily revolves around devices designed for minimally invasive valve replacement procedures, which are increasingly preferred over traditional open ...

TAVR is a dynamic field ... we did a first-in-human trial of a transcatheter mitral valve replacement device. Now there are more than 20 mitral valve replacement devices in clinical trials ...

In particular, research on Edwards' market-leading Sapien TAVR device suggests that the learning curve is 200 cases. That's the inflection point where the physician can deliver optimal patient ...

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices. Investors remain bullish on ...

The UHS Heart & Vascular Institute recently celebrated a significant milestone with the completion of their 1,000th TAVR (Transcatheter Aortic Valve Replacement) procedure. This achievement is ...

commercially available TAVR devices will be implanted in patients who would otherwise be candidates only for open-heart surgery. The study will compare this newly acquired TAVR data to historical ...

Minimally invasive heart procedures like transcatheter aortic valve replacement (TAVR) and MitraClip placement to treat mitral regurgitation can improve quality of life, and even be lifesaving, for ...

The firm recently retrenched in the transcatheter aortic valve market after discontinuing its Lotus device. Though we're not particularly optimistic about its new Acurate Neo TAVR franchise ...

The STS used recent national data from the STS Adult Cardiac Surgery Database between 2012 and 2023 to analyze outcomes of SAVR after previous TAVR. The analysis of 5,457 patients reported an ...